Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04678505 · ClinicalTrials.gov registry record · Phase 1
Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04678505 is a Phase 1 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 9 participants.
The verdict
NCT04678505, a Phase 1 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the plasma and urine pharmacokinetics (PK) of MK-3402 in participants with impaired renal function and healthy control participants, to investigate the extent to which MK-3402 is removed from the plasma by hemodialysis (HD), and evaluate the safety and tolerability of MK-3402 in participants with impaired renal function.
Interventions
- DRUG MK-3402
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2021-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04678505
The ClinicalTrials.gov registry entry for NCT04678505 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MK-3402 is the first listed.
NCT04678505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04678505 about?
NCT04678505 is a clinical study titled "Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)". The purpose of this study is to compare the plasma and urine pharmacokinetics (PK) of MK-3402 in participants with impaired renal function and healthy control participants, to investigate the extent to which MK-3402 is removed from the plasma by hemodialysis (HD), and evaluate the safety and tolerab...
What is the current status of trial NCT04678505?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-02-10. Estimated completion is 2021-04-27.
What interventions are being tested in trial NCT04678505?
The interventions under investigation include: MK-3402 (DRUG).
Who is sponsoring clinical trial NCT04678505?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.